NEW YORK (GenomeWeb News) – Assurex Health has created a public-private partnership with Canada's Centre for Addiction and Mental Health (CAMH) to offer the firm's pharmacogenomic test to help guide psychiatric treatments, the company said yesterday.

Assurex Health and CAMH have launched the joint venture AssureRx Canada to provide the GeneSight test, which measures and analyzes genomic variants to help physicians select the appropriate treatments for depression, anxiety, bipolar disorder, schizophrenia, and other neuropsychiatric conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.